Abstract: A metal organic framework and a method for preparing the same, and an adsorption device employing the metal organic framework are provided. The metal organic framework includes a 3,5-pyridinedicarboxylic acid and a metal ion, which is an aluminum ion, a chromium ion, or a zirconium ion, wherein the 3,5-pyridinedicarboxylic acid is coordinated to the metal ion.

Abstract: A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprise administering the mixed metal complex to the patient.

Abstract: The metal complex comprises a multivalent carboxylic acid compound, at least one metal ion selected from ions of metals belonging to Groups 2 to 13 of the periodic table, an organic ligand capable of multidentate binding to the metal ion, and a C1 or C2 monocarboxylic acid compound. The metal complex has excellent gas adsorption, storage, and separation performance as well as excellent durability. The metal complex is stably present under high temperature and high humidity, and can maintain high adsorption performance.

Abstract: The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes a diversity element which potentially binds to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the diversity element. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to said diversity element, and is capable of forming a reversible covalent bond or non-covalent interaction with a binding partner of the linker element. The monomers can be covalently or non-covalently linked together to form a therapeutic multimer or a precursor thereof. Also disclosed is a method of screening for therapeutic multimer precursors which bind to a target molecule associated with a condition and a method of screening for linker elements capable of binding to one another.

Abstract: Provided herein are porous single-molecule trap materials with fixed pore sizes that are capable of trapping one molecule per cavity.

Abstract: There is provided a method and nanocomposite for the reversible assembly of nanotubes, such as oxidized single wall carbon nanotubes, based on metal coordination. The method produces a thermally stable, neutral nanocomposite possessing enhanced mechanical, electrical, physical and chemical properties for example. Disassembly can be provided by treatment with a competing ligand compound.

Abstract: A negative electrode active material for a sodium-ion battery includes a compound including an aromatic ring structure and two or more COOX groups in which X is Li or Na, and which are bonded to ends of the aromatic ring structure, the aromatic ring structure including an aromatic heterocyclic ring that contains nitrogen in the ring.

Abstract: The invention relates to complexes of germanium with amino acids and carboxylic acids of the general formula Ge[OH]a[AA]b[CA]c (I), where AA is an amino acid, CA is a carboxylic acid, a=0-3, b=1-3, c=0-3, and 1<b+c?4, wherein AA and AC in the complex can be identical or different, and to a method for preparing same. The method preparing an aqueous suspension of germanium dioxide, adding an amino acid and a carboxylic acid to the aqueous suspension of germanium oxide produced, heating the mixture produced with agitation at a temperature of 40-100° C. for 2-14 hours with subsequent filtering, removal of the water and production of a complex in solid form. The method makes it possible to prepare stable complexes with a controllable composition and a control fable ratio of germanium to amino acid and carboxylic acid which are stable in solid form and can be used in medicine.

Abstract: A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: (Formula I) (I) wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering the mixed metal complex to the patient.

Abstract: The present invention relates to iron and manganese complexes based on hexadentate ligand systems containing one carboxylato donor and five nitrogen donor atoms and to their use in methods for the catalysis of the oxidation of organic substrates. The manganese complexes of the invention also may be used as (pro)-catalysts in methods for the catalysis of water.

Abstract: Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.

Abstract: The present invention concerns complexing agents of formula (I) in which a, b, c, chrom1, chrom2, chrom3, R3, R4 and R5 are as defined in the description. The invention also concerns lanthanide complexes comprising said complexing agents, as well as a method for synthesizing said agents.

Abstract: Provided are an organometallic complex providing highly efficient phosphorescence and an organic electroluminescence device using the same. The organometallic complex can be used to form an organic layer of the organic electroluminescence device, efficiently emits light of a wavelength corresponding to red light, and has high brightness and low operating voltage.

Abstract: An organic electroluminescent compound containing Iridium, preparation method thereof and an organic electroluminescent device are disclosed. The compound is represented by the structure (2), wherein, R is C1˜C4 alkyl. The structure of the compound contains bipyridine ligand, also carries alkoxy group and fluorine atom, which improves its carrier injection and transfer ability, and increases its internal quantum efficiency and electroluminescent efficiency. Furthermore, the compound uses strong field ligand 2-pyridine carboxylic acid as assistant ligand, which causes an effective blue shift of its emission spectrum and increases light-emitting efficiency of blue light phosphorescence greatly.

Abstract: The present invention relates to oxadiazole metallic complexes. More specifically it relates to the synthesis and electronic and opto-electronic applications of oxadiazole metallic complexes having a general Formula I, wherein each of variables is defined herein.

Abstract: The invention provides an iridium-containing organic electroluminescent material, the formula of which is H: wherein R is C1-C8 alkyl. The molecule of the iridium-containing organic electroluminescent material contains benzimidazole group with electron transmission function and the benzimidazole has alkyl and fluorobenzyl group, which can improve the electron injection and transmission function of the electroluminescent material, and enable the electroluminescent material to have higher internal quanta efficiency and electroluminescent efficiency. The invention also provides a preparation method of the iridium-containing organic electroluminescent material, and an organic electroluminescent device using the material.

Abstract: An organometallic complex represented by Chemical Formula 1: wherein M, CyN, CyC, X1, X2, R1 to R4, R? and n are described in the specification.

Abstract: The present disclosure relates to novel pharmaceutical compositions comprising a nanoparticle associated with, tether to, or encapsulating a platinum-based active pharmaceutical agent. The platinum-based drug is released from the nanoparticles in a controlled fashion. Also contemplated are methods of making the nanoparticles, as well as methods for using them in the treatment or prevention of diseases or conditions. One embodiment relates to phenanthriplatin nanoparticles and methods of using and making the same.

Abstract: The present invention relates to the field of catalysis and, more particularly, to a ruthenium carbonate complex of formula [Ru(diene)(C03)] or [Ru(diene)(C03)2]Mn, wherein M is an alkaline (n is 2) or alkaline earth (n is 1) cation. The invention relates also to the use of said ruthenium carbonate complex as precursors for a number of Ru carboxylate complexes. Said specific ruthenium complexes possess a number of important advantages over the similar prior art known precursors.

Abstract: The present invention relates to the use of dithiocarbamate compounds and to an assembly for use in an electronic device, said assembly comprising a self-assembled monolayer of at least one dithiocarbamate compound. The present invention also relates to an electronic device including such assembly.

Abstract: This invention relates to complexes of certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including molybdenum, having a hydroxy acid [HA] and an amino acid [AA] moiety concurrently bound to a single said metal and having a spirocyclic, bidentate chelate structure of formula (I). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation.

Abstract: The invention provides an iridium-containing organic electroluminescent material, the formula of which is H: wherein R is C1-C8 alkyl. The molecule of the iridium-containing organic electroluminescent material contains benzimidazole group with electron transmission function and the benzimidazole has alkyl and fluorobenzyl group, which can improve the electron injection and transmission function of the electroluminescent material, and enable the electroluminescent material to have higher internal quanta efficiency and electroluminescent efficiency. The invention also provides a preparation method of the iridium-containing organic electroluminescent material, and an organic electroluminescent device using the material.

Abstract: Disclosed herein are mixed metal-organic frameworks, Zn3(BDC)3[Cu(SalPycy)] and Zn3(CDC)3[Cu(SalPycy)], wherein BDC is 1,4-benzenedicarboxylate, CDC is 1,4-cyclohexanedicarboxylate, and SalPyCy is a ligand of the formula: These are useful for applications such as selective gas storage, selective molecular separations, and selective detection of molecules, including enantioselective applications thereof.

Abstract: The present invention provides a metal complex of group 10 elements of the periodic table having a carboxylate structure represented by formula (C2); a catalyst for polymerization of olefin mainly comprising the metal complex; and a method for producing polymers by homopolymerizing olefin represented by formula (1), polymerizing two or more kinds of the above olefin, or copolymerizing olefin represented by formula (1) with polar group-containing olefin represented by formula (2) (the meaning of the symbols are as set forth in the description) using the catalyst. A metal complex of group 10 elements of the periodic table, in which all of the coordinating atoms to the metal are a hetero atom is stable and useful as a catalyst component for olefin polymerization, and can be used for a long time in homopolymerization of olefin or copolymerization of two or more kinds of olefin.

Abstract: A system and method for systematically generating potential metal-organic framework (MOFs) structures given an input library of building blocks is provided herein. One or more material properties of the potential MOFs are evaluated using computational simulations. A range of material properties (surface area, pore volume, pore size distribution, powder x-ray diffraction pattern, methane adsorption capability, and the like) can be estimated, and in doing so, illuminate unidentified structure-property relationships that may only have been recognized by taking a global view of MOF structures. In addition to identifying structure-property relationships, this systematic approach to identify the MOFs of interest is used to identify one or more MOFs that may be useful for high pressure methane storage.

Abstract: The present invention relates to the field of catalysis and, more particularly, to a ruthenium carbonate complex of formula [Ru(diene)(C03)] or [Ru(diene)(C03)2]Mn, wherein M is an alkaline (n is 2) or alkaline earth (n is 1) cation. The invention relates also to the use of said ruthenium carbonate complex as precursors for a number of Ru carboxylate complexes. Said specific ruthenium complexes possess a number of important advantages over the similar prior art known precursors.

Abstract: A synthetic method for preparing organometallic iridium compounds is provided and includes the two steps of (1) synthesizing a di-iridium compound with a halogenated bridge: L2Ir(??X)2IrL2, L; and (2) reacting L2Ir(??X)2IrL2 with a ligand to give the product [C?]N]2Ir (LX). The invention is an improvement over the traditional method for preparing such compounds and has the advantages of shortened reaction time, increased yield, and products of over 99% purity obtained without chromatography.

Abstract: An organometallic complex [Cu2(pyridine-3,5-dicarboxylate)2]n is provided by bonding a plurality of Cu2(pyridine-3,5-dicarboxylate)2 repeating units to each other. The organometallic complex can be obtained by the steps of dissolving copper acetate monohydrate or anhydrate and pyridine-3,5-dicarboxylic acid in a solvent, heating the solution at 50° C. to 140° C. for 24 to 168 hours to generate a reaction product, and then removing a guest molecule from the reaction product.

Abstract: The present invention provides for the purposeful utilisation of the induction of senescence in eukaryotic cells for induction of an antigen specific immune response. Such cells can be normal cells, pre-malignant and malignant cells as well as virally or bacterially infected cells, for the generation of an immune response, preferably a cellular or humoral immune response comprising T-cells and/or B-cells, whose immune response is directed specifically against antigens from those cells in which senescence was induced and then comprises an immune response against the senescent cells itself as well as to the non-senescent counterparts harbouring the same antigens.

Abstract: The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitable for therapeutic oral administration.

Abstract: This invention relates to complexes of certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including molybdenum, having a hydroxy acid [HA] and an amino acid [AA] moiety concurrently bound to a single said metal and having a spirocyclic, bidentate chelate structure of formula (I). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation.

Abstract: This invention provides polymeric coordination compounds capable of forming three-dimensional microporous metal organic frameworks (MMOFs) that are useful for detection of explosive compounds. The polymeric coordination compounds comprise a repeating unit comprising a transition metal coordinated to at least one binding member of a bidentate binding site on each of two polyfunctional ligands and one binding site of a bis-pyridine exodentate bridging ligand, for example, the repeating unit comprising formula [Zn2(bpdc)2(bpee)] (bpdc=4,4?-biphenyldicarboxylate; bpee=1,2-bipyridylethene). Methods of preparing such polymeric coordination compounds, methods of using them for detection of explosive compounds, and sensors or sensor arrays comprising such polymeric coordination compounds for detection of explosive compounds, especially those comprising one or more nitro (—NO2) groups, are also disclosed.

Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.

Abstract: Bis-(4,4?dimethyl-2,2?bipyridyl) picolinate osmium complexes are useful as mediators in the electrochemical test strips, such as those used in the detection of glucose.

Abstract: The present invention provides compositions and methods based on vital fluorochrome conjugates that are useful for imaging dying and dead cells.

Abstract: A light emitting material comprising a complex of formula (I): (L1)x-M-(L2)y wherein L1 is a mono-anionic bidentate carbon-coordinating ligand comprising the structural element (II) in a ring system, wherein R1 is a substituent selected from the group consisting of R1-1 to R1-8, the use thereof as emissive materials in organic light emitting devices, and organic light emitting devices comprising said emissive material.

Abstract: The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

Abstract: An electrochromic material including a metal-organic framework including a metal, and an organic compound including a functional group, wherein the organic compound forms a coordination complex with the metal.

Abstract: Provided are an organic electroluminescence device whose wavelength of light emission is short and which can emit blue light having a high color purity, and a metal complex compound for realizing the device. The metal complex compound is of a specific structure having a partial structure including two tridentate ligands. The organic electroluminescence device includes: a pair of electrodes; and an organic thin film layer which has one layer or a plurality of layers including at least a light emitting layer and is disposed between the pair of electrodes. In the organic electroluminescence device, at least one layer of the organic thin film layer contains the metal complex compound. The organic electroluminescence device emits light by applying a voltage between both the electrodes.

Abstract: The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-?B dysregulation.

Abstract: Copper (I) chloride complex of nicotinic acid and pharmaceutical compositions containing the same. Such pharmaceutical composition are effective for the treatment of myopathy, myasthenia gravis, parkinsonism, Chronic Fatigue Syndrome, Male Infertility and post stroke muscle weakness, muscular dystrophy, skin burns, scars, alopecia, high blood lipids and obesity.

Abstract: The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds.

Abstract: Bis-(4,4?dimethyl-2,2?bipyridyl) picolinate osmium complexes are useful as mediators in the electrochemical test strips, such as those used in the detection of glucose.

Abstract: Provided is a material for organic electroluminescence device containing (a) a phosphorescent metal complex containing a monoanionic bidentate ligand and a metal having an atomic weight of 40 or greater, wherein the monoanionic bidentate ligand is represented by the following formula (A): wherein, each of E1a, E1d, E1e, E1f, E1k, E1l, E1p, and E1q independently represents a carbon atom or a hetero atom, each of Z1, Z2, and Z3 independently represents an aromatic ring or aromatic heterocycle, the aromatic ring or aromatic heterocycle may have a substituent, and a skeleton represented by the formula (A) has, in total, a 18? electron structure, and the bidentate ligand represented by the formula (A) may be coupled to another ligand to form a tridentate or higher-dentate ligand; and (b) a structural isomer represented by the same chemical formula as that of the phosphorescent metal complex (a) but different sterically in a coordination method of the ligand, wherein the structural isomer (b) is contained in

Abstract: The present invention relates to the use of dithiocarbamate compounds and to an assembly for use in an electronic device, said assembly comprising a self-assembled monolayer of at least one dithiocarbamate compound. The present invention also relates to an electronic device including such assembly.

Abstract: The present invention relates to a platinum complex as the following formula (I): wherein X, n, R1, R2, R3,R4, R5, X1, X2, L1, and L2 are defined the same as the specification. The present invention also further provides an organic light-emitting device using the same. The complexes of the present invention exhibit enhanced emission quantum yields, and short phosphorescence radiative lifetimes in the range of several microseconds so as to be applied in high efficiency OLEDs.

Abstract: A photosensitizing transition metal complex of the formula (Ia) MLY1, (Ib) MLX3 (Ic) MLY2X, (Id) MLY3X or (Ie) MLY4X in which M is a transition metal selected from ruthenium, osmium, iron, rhenium and technetium, preferably ruthenium or osmium. X is a co-ligand independently selected from NCS—, Cl—, Br—, I—, CN—, H2O; pyridine unsubstituted or substituted by at least one group selected from vinyl, primary, secondary or tertiary amine, OH and C1-30 alkyl, preferably NSC and CN—; L is a tridentate polypyridine ligand, carrying at least one carboxylic, phosphoric acid or a chelating group and one substituted or unsubstituted alkyl group having 1 to 50 carbon atoms, substituted or unsubstituted alkylamide group having 2 to 30 carbon atoms or substituted or unsubstituted aralkyl group having 7 to 50 carbon atoms.

Abstract: A green phosphorescent iridium complex represented by Formula (I) is provided. In Formula (I), R1, R2 and R3 are, independently, hydrogen, halogen, substituted or non-substituted C1-6 alkyl, C1-6 alkoxy, cycloalkyl, substituted or non-substituted aryl, amino or heteroaryl, and L is a heterocyclic ring containing N—N or N—O ligand. The invention also provides a method for fabricating the green phosphorescent iridium complex and an organic light-emitting diode including the green phosphorescent iridium complex.

Abstract: A photosensitizing transition metal complex of the formula (Ia) MLY1, (Ib) MLX3 (Ic) MLY2X, (Id) MLY3X or (Ie) MLY4X in which M is a transition metal selected from ruthenium, osmium, iron, rhenium and technetium, preferably ruthenium or osmium. X is a co-ligand independently selected from NCS—, Cl—, Br—, I—, CN—, H2O; pyridine unsubstituted or substituted by at least one group selected from vinyl, primary, secondary or tertiary amine, OH and C1-30 alkyl, preferably NSC and CN—; L is a tridentate polypyridine ligand, carrying at least one carboxylic, phosphoric acid or a chelating group and one substituted or unsubstituted alkyl group having 1 to 50 carbon atoms, substituted or unsubstituted alkylamide group having 2 to 30 carbon atoms or substituted or unsubstituted aralkyl group having 7 to 50 carbon atoms.

Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials, dental bonding agents or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such dental restorative materials may help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.